Aytu BioPharma, Inc. (NASDAQ:AYTU – Get Rating) passed below its 50 day moving average during trading on Friday . The stock has a 50 day moving average of $0.57 and traded as low as $0.52. Aytu BioPharma shares last traded at $0.56, with a volume of 321,899 shares changing hands.
Analyst Upgrades and Downgrades
A number of research analysts have commented on the stock. HC Wainwright cut their target price on shares of Aytu BioPharma from $11.00 to $6.00 and set a “buy” rating on the stock in a research report on Thursday, July 21st. Cantor Fitzgerald lowered their price target on shares of Aytu BioPharma from $11.00 to $5.00 in a report on Tuesday, May 17th.
Aytu BioPharma Stock Up 6.2 %
The business’s 50 day moving average is $0.57 and its 200 day moving average is $0.84. The company has a market capitalization of $21.60 million, a price-to-earnings ratio of -0.14 and a beta of -0.42. The company has a debt-to-equity ratio of 0.30, a quick ratio of 0.80 and a current ratio of 0.97.
Institutional Trading of Aytu BioPharma
A hedge fund recently raised its stake in Aytu BioPharma stock. Renaissance Technologies LLC raised its holdings in shares of Aytu BioPharma, Inc. (NASDAQ:AYTU – Get Rating) by 15.1% in the 1st quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The firm owned 765,469 shares of the company’s stock after acquiring an additional 100,400 shares during the period. Renaissance Technologies LLC owned approximately 2.29% of Aytu BioPharma worth $827,000 at the end of the most recent quarter. 11.47% of the stock is owned by institutional investors.
About Aytu BioPharma
Aytu Biopharma, Inc, a specialty pharmaceutical company, focuses on developing and commercializing novel therapeutics and consumer healthcare products the United States and internationally. The company offers Adzenys XR-ODT for the treatment of attention deficit hyperactivity disorder (ADHD) in patients from 6 years and older; Cotempla XR-ODT for the treatment of ADHD in patients from 6 to 17 years old; and Adzenys ER, an oral suspension for the treatment of ADHD in patients from 6 years and older.
- Get a free copy of the StockNews.com research report on Aytu BioPharma (AYTU)
- MarketBeat: Week in Review 8/1 – 8/5
- How to Use High Beta Stocks to Maximize Your Investing Profits
- Cronos Group Inc’s Revenues Are Up, Is It Time to Buy?
- Why Apple Could Be At All-Time Highs By Year End
- Beyond Meat Is Not Beyond Hope, And It’s Cheap
Receive News & Ratings for Aytu BioPharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aytu BioPharma and related companies with MarketBeat.com's FREE daily email newsletter.